On March 16, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for B-cell lymphomas.
The version 3.2021 update features updates for follicular lymphoma.
Under suggested treatment regimens, regimens from second-line and subsequent therapy were separated into new headings for clarity: third-line and subsequent therapy and third-line and subsequent therapy for elderly or infirm.
Additionally, “anti CD-19 CAR T-cell therapy (only after ≥2 line of systemic therapy” was added as a bullet under third-line and subsequent therapy, with axicabtagene ciloleucel added as a category 2A other recommended regimen.—Janelle Bradley
